Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0018799 (
heart disease
)
34,133
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The
estrogen-related receptor alpha
(
ERRalpha
) is an orphan nuclear receptor (ONR) that by binding to DNA sites controls gene expression in association with coactivators and corepressors.
ERRalpha
was the first ONR to be identified; however, its natural endogenous ligand(s) is still unknown.
ERRalpha
by acting as a transcription factor has been shown to regulate a large array of genes, thereby controlling numerous metabolic pathways and other biological functions in animals. Of late, the expression of
ERRalpha
has been detected in several tissues, including those with high metabolic activities and energy demand. Presently, the control of energy balance by
ERRalpha
seems to be its prime role. The nonavailability of endogenous ligand for
ERRalpha
has not impeded the study of its functions. In fact, most of the present knowledge of the biological roles of
ERRalpha
has evolved from in-depth biochemical, overexpression, genomic, including functional genomics studies, and also through the generation of intact
ERRalpha
knockout (null) mice. Interestingly, over the past few years, growing evidence suggests interplay between
ERRalpha
and various human metabolic diseases such as diabetes, obesity, and
heart disease
. Also, there are strong indications of the involvement of
ERRalpha
in cancer initiation and progression. Interestingly, this makes
ERRalpha
a suitable, direct target for pharmacological intervention in treating such diseases. This review focuses on the overall developments and recent advances in understanding the role of
ERRalpha
in metabolism and other biological functions, including its role in human diseases.
...
PMID:The estrogen-related receptor alpha: the oldest, yet an energetic orphan with robust biological functions. 2049 91